Literature DB >> 7959673

A case of neural cell adhesion molecule-positive peripheral T-cell lymphoma associated with human T-cell lymphotrophic virus type 1 showing an unusual involvement of the gastrointestinal tract during the course of the disease.

K Hayashi1, S Nakamura, T Koshikawa, K Kitoh, K Koike, H Komatsu, M Kuroda, M Kasahara, R Ueda, T Suchi.   

Abstract

We report a case of neural cell adhesion molecule (NCAM)-positive peripheral T-cell lymphoma (PTCL), pleomorphic, medium and large cell type according to the updated Kiel classification, which was associated with human T-cell lymphotrophic virus type 1 (HTLV-1). The patient showed an unusual involvement of the gastrointestinal tract forming a bulky mass during the course of his disease, and a relatively indolent clinical course for 53 months until death. Phenotypic analysis showed CD2+, CD3-, CD4+, CD5+, CD7+, CD8-, CD16-, CD56+, and CD57- phenotype. Human T-cell lymphotrophic virus type 1 antibody was detected by the enzyme-linked immunosorbent assay. The proviral integration of HTLV-1 and the monoclonal rearrangements of T-cell receptor beta and gamma genes also were confirmed in DNA extract from fresh material. This fact calls attention to NCAM as one of the potential factors playing a role in the localization and behavior of lymphomas even within the category of PTCL associated with HTLV-1, ie, adult T-cell leukemia/lymphoma (ATLL).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7959673     DOI: 10.1016/0046-8177(94)90045-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

Review 1.  CD56-positive adult T-cell leukemia/lymphoma: a case report and a review of the literature.

Authors:  Kei-Ji Sugimoto; Asami Shimada; Mutsumi Wakabayashi; Yasunobu Sekiguchi; Noriko Nakamura; Tomohiro Sawada; Yasunori Ota; Norio Komatsu; Masaaki Noguchi
Journal:  Med Mol Morphol       Date:  2014-03-28       Impact factor: 2.309

2.  The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.

Authors:  Ana Paula Alegretti; Christina Matzenbacher Bittar; Rosane Bittencourt; Amanda Kirchner Piccoli; Laiana Schneider; Lúcia Mariano Silla; Suzane Dal Bó; Ricardo Machado Xavier
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 3.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.